Johnson: Goal of ‘right to try’ bill is to diminish role of FDA
A key goal of legislation aimed at providing more ways for terminally ill patients to get access to experimental therapies is to diminish the role of the Food and Drug Administration, Sen. Ron Johnson, R-Wis., said in a blunt letter last week to Commissioner Scott Gottlieb.
To access this content, you must purchase a Premium membership, or log in if you are a member.
